Abstract:In the field of medicinal chemistry, the discovery of novel compounds with therapeutic potential is of utmost importance. However, the conventional approach to drug discovery, relying on high-throughput screening (HTS), encounters limitations such as reagent availability and labor costs. Although a hit-finding campaign starts with a virtual screen of millions of compounds, the hit-to-lead and lead optimization stages often require designing, synthesizing, and profiling thousands of analogs before selecting clinical candidates. Recent advances offer an innovative solution - the virtual generation of billions of synthetically feasible compounds with an impressive 80% success rate for synthesis. This breakthrough has the potential to significantly expand the chemical space available for purchase and experimental validation, bringing about a revolution in the field. Our study presents a comprehensive approach to compound discovery and optimization, harnessing quantitative high-throughput screening (qHTS), chemical databases, and reaction-based enumeration. To further enhance the synthesis process and gain deeper insights into compound formation, we utilize the Reaction Cookbook from Biosolveit, which comprises reaction SMARTs for around 300 chemical reactions. By employing this wide range of reactions, we aim to uncover the full spectrum of a chemotype's potential and customize its structure to optimize desired properties. As an illustration of this approach, our work on the ALDH3A1 project resulted in the synthesis of 50 compounds, with 21 of them exhibiting activity (negative curve class values; hit-rate ~42%). Among these active compounds, 6 displayed IC50 values lower than 30 µM and efficacy values less than -50%, with the most potent compound achieving an impressive potency of 447 nM. This study demonstrates the successful synergy between in-silico reaction-based analogs enumeration, molecular modeling and AI/ML-based techniques in identifying compounds with improved biological activity, offering promising prospects for the development of ALDH3A1-targeting agents as potential cancer therapeutics. Computational workflows developed in this study can be used for similar target-based drug discovery campaigns.

Path Toward High-Throughput Synthesis Planning via Performance Benchmarking

Routescore: Punching the Ticket to More Efficient Materials Development

Data-driven automatic synthesis planning: Synthesis routes of S-Zanubrutinib identified with CDI CASP

Exploring Novel Biologically-Relevant Chemical Space Through Artificial Intelligence: The NCATS ASPIRE Program

Learning to Plan Chemical Syntheses

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

Constrained synthesis planning with disconnection-aware transformer and multi-objective search

Biosynth Pipeline: An integrated platform for merging the computational design of chimeric type I polyketide synthases with enzymatic pathways for chemical biosynthesis

Integrating synthetic accessibility with AI-based generative drug design

Planning chemical syntheses with deep neural networks and symbolic AI

DirectMultiStep: Direct Route Generation for Multi-Step Retrosynthesis

AI-driven drug discovery: identification and optimization of ALDH3A1 selective inhibitors with nanomolar activity

Chemoenzymatic synthesis planning by evaluating the synthetic potential in biocatalysis and chemocatalysis

GRASP: Navigating Retrosynthetic Planning with Goal-driven Policy

Active Retrosynthetic Planning Aware of Route Quality

Catalyst: Curtailing the scalable supply of fentanyl by using chemical AI

The Process of AI-Aided Drug Design

Site-Specific Template Generative Approach for Retrosynthetic Planning

Challenging Complexity with Simplicity: Rethinking the Role of Single-Step Models in Computer-Aided Synthesis Planning

SynCluster: Reaction Type Clustering and Recommendation Framework for Synthesis Planning

Re-evaluating Retrosynthesis Algorithms with Syntheseus